Literature DB >> 17383307

Evolution of 5 cardiovascular magnetic resonance-derived viability indexes after reperfused myocardial infarction.

Vicente Bodí1, Juan Sanchis, Maria P Lopez-Lereu, Julio Nunez, Luis Mainar, Mauricio Pellicer, Roberto Sanz, Cristina Gomez, Maria J Bosch, Oliver Husser, Francisco J Chorro, Angel Llacer.   

Abstract

BACKGROUND: The objective of this study was to evaluate the simultaneous evolution of 5 cardiovascular magnetic resonance-derived myocardial viability indexes.
METHODS: We studied 72 patients with a first ST-elevation myocardial infarction and sustained TIMI 3 flow. In the first week and in the sixth month of the study, using cardiovascular magnetic resonance imaging, we determined wall thickening (WT) and the following viability indexes: wall thickness, WT with low-dose dobutamine, microvascular perfusion in first-pass imaging, microvascular obstruction in late-enhancement imaging, and transmural extent of necrosis.
RESULTS: In 250 dysfunctional segments, the evolution outcomes for the viability indexes were as follows: (1) wall thickness thinned (8.6 +/- 2.9 versus 7.7 +/- 3 mm, P < .001), (2) WT with low-dose dobutamine improved (1.5 +/- 1.9 versus 2.6 +/- 3 mm, P < .001), (3) the number of segments showing abnormal microvascular perfusion in first-pass imaging decreased (22% versus 7%, P < .001), (4) the number of segments showing microvascular obstruction in late-enhancement imaging decreased (14% versus 2%, P < .001), and (5) the transmural extent of necrosis remained stable throughout follow-up (56% +/- 40% versus 54% +/- 39%, P = .3).
CONCLUSIONS: After reperfused myocardial infarction, dynamic changes in wall thickness, contractile reserve, microvascular perfusion, and microvascular obstruction take place. These changes may affect their accuracy as viability indexes early after myocardial infarction. The transmural extent of necrosis does not vary, however.

Entities:  

Mesh:

Year:  2007        PMID: 17383307     DOI: 10.1016/j.ahj.2006.12.023

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  5 in total

1.  Head to head comparison of quantitative versus visual analysis of contrast CMR in the setting of myocardial stunning after STEMI: implications on late systolic function and patient outcome.

Authors:  Oliver Husser; Vicente Bodi; Juan Sanchis; Julio Nunez; Luis Mainar; Pilar Merlos; Maria P Lopez-Lereu; Jose V Monmeneu; Fabian Chaustre; Eva Rumiz; Günter A J Riegger; Francisco J Chorro; Angel Llacer
Journal:  Int J Cardiovasc Imaging       Date:  2010-02-20       Impact factor: 2.357

2.  Function of remote non-infarcted myocardium after STEMI: analysis with cardiovascular magnetic resonance.

Authors:  Oliver Husser; Fabian Chaustre; Juan Sanchis; Julio Nunez; Jose V Monmeneu; Maria P Lopez-Lereu; Clara Bonanad; Cristina Gomez; Ricardo Oltra; Angel Llacer; Günter A J Riegger; Francisco J Chorro; Vicente Bodi
Journal:  Int J Cardiovasc Imaging       Date:  2012-01-20       Impact factor: 2.357

3.  White blood cell subtypes after STEMI: temporal evolution, association with cardiovascular magnetic resonance--derived infarct size and impact on outcome.

Authors:  Oliver Husser; Vicente Bodi; Juan Sanchis; Julio Nunez; Luis Mainar; Francisco Javier Chorro; Maria Pilar Lopez-Lereu; Jose Vicente Monmeneu; Fabian Chaustre; Maria J Forteza; Isabel Trapero; Francisco Dasi; Isabel Benet; Günter A J Riegger; Angel Llacer
Journal:  Inflammation       Date:  2011-04       Impact factor: 4.092

Review 4.  Thrombus aspiration in primary angioplasty for ST-segment elevation myocardial infarction.

Authors:  Roberta Serdoz; Michele Pighi; Nikolaos V Konstantinidis; Ismail Dogu Kilic; Sara Abou-Sherif; Carlo Di Mario
Journal:  Curr Atheroscler Rep       Date:  2014-08       Impact factor: 5.113

5.  Cardiac magnetic resonance imaging analysis in STEMI: quantitative or still visual?

Authors:  E E van der Wall; J J Bax; J H Reiber
Journal:  Int J Cardiovasc Imaging       Date:  2010-05-08       Impact factor: 2.357

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.